Medical Analysis

Serum Alanine Transferase (ALT)

Introduction: Understanding ALT (SGPT) and Liver Health

Serum Alanine Transferase, commonly known as Serum Glutamate Pyruvate Transaminase (SGPT), is an essential enzyme primarily found in the liver [2]. Because of its high concentration in hepatic tissues, any form of liver cell injury or disease leads to its release into the bloodstream [2, 15]. This enzyme plays a crucial role in amino acid metabolism, facilitating biochemical processes necessary for the body’s energy production [2].

Clinicians often order an ALT test alongside other biomarkers—such as AST, ALP, and bilirubin—to comprehensively diagnose and monitor liver health [5, 6]. Notably, some forms of liver disease cause ALT levels to rise significantly before a patient experiences any clinical symptoms, making this test a vital tool for early detection [5].

Biochemical Reaction: How ALT Functions

ALT catalyzes a fundamental reversible transamination reaction, which is essential for amino acid metabolism and energy production [2]. In this process, the enzyme transfers an amino group from L-alanine to a-ketoglutarate.

Clinical Insights: The De Ritis Ratio and Liver Assessment

The De Ritis ratio, which compares the levels of Aspartate Aminotransferase (AST) and Alanine Transferase (ALT), is an invaluable tool for physicians assessing the underlying cause of liver enzyme abnormalities [3]. Understanding the localization of these enzymes is key: AST is located primarily in the mitochondria of liver cells, whereas ALT exists mainly in the cytoplasm [3].

Normally, the AST/ALT ratio is less than 1, typically falling between 0.7 and 0.9 [3]. However, when the ALT/AST ratio exceeds 1, it serves as a critical indicator that liver cell injury must be considered, and timely treatment planning is required [3, 6]. In cases of infectious hepatitis, inflammatory conditions, and cirrhosis, ALT is often equal to or higher than AST, causing the ratio to exceed 1.5 [3, 6]. Conversely, an AST/ALT ratio higher than 2:1 is a common diagnostic hallmark of alcoholic liver disease [3, 6]. Physicians must monitor these ratios closely; for instance, as a ratio begins to reverse, it may signal the development of chronic hepatitis or cirrhosis [3, 10].

De Ritis Ratio in Various Organs

The distribution and ratio of these enzymes vary significantly across different body tissues [3]:

Pathophysiology: Why ALT Levels Rise

While ALT is widely distributed throughout the body, it is found predominantly in the cytoplasm of hepatic parenchymal cells, making it a highly specific biomarker for liver health [2]. The concentration of ALT activity within the liver is approximately 3,000 times higher than its activity in the serum [2]. Under normal conditions, ALT remains within the cells; however, only when these cells are damaged is the enzyme excreted into the bloodstream [2, 5]. Once in the plasma, ALT serves no biological function because the necessary substrates and co-substrates are absent in the blood [2].

Indication of Estimation: When to Test for Liver Damage

The estimation of ALT is indicated when a patient presents with symptoms of potential liver damage or falls into a high-risk category [2, 5].

Symptoms of Liver Damage

If you experience the following, a doctor may recommend an ALT test [2, 5]:

• Persistent nausea and vomiting

• Lack of appetite

• Unexplained fatigue or weakness

• Jaundice (yellowing of skin and eyes)

• Abdominal pain or swelling

• Swelling in the ankles and legs

• Dark-colored urine or light-colored stool

• Frequent, persistent itching

High-Risk Groups

Routine monitoring is often necessary for individuals with [2, 11, 15]:

• Family history of liver disease

• Alcohol abuse disorder (AUD)

• Obesity and metabolic syndrome

• Diabetes

• Use of medications known to be hepatotoxic (liver-damaging)

• History of Hepatitis or exposure to the virus

• Fatty Liver Disease

Blood Sample Collection and Patient Preparation

Proper patient preparation is essential for accurate results [2]. Patients are advised to avoid alcohol and high-lipid diets before testing [2]. Strenuous exercise and intramuscular injections should also be avoided, as these can artificially increase enzyme levels [2, 5]. Because red blood cells contain ALT, hemolysis (the rupture of blood cells) during collection can falsely elevate serum ALT levels, a factor that must be considered during clinical interpretation [2].

Collection Protocol:

• Collect 3.0 ml of blood in a plain, red-capped tube [2].

• Separate the serum as quickly as possible and transport it to the laboratory for processing [2].

Methods of Estimation

Several established laboratory techniques are used to measure ALT activity [2]:

• Karment’s method

• Reitman-Frankel method

• King’s method

• Mohun’s method

• Spectrophotometric analysis

• Immunoassay

• UV-Kinetic method

Reference Ranges and Clinical Correlation

Clinical interpretation of ALT levels depends on standardized ranges, though these may vary by laboratory and methodology [2, 4].

Clinical Relevance and Causes of Abnormal ALT

The following table summarizes the relationship between clinical conditions and ALT/AST findings:

Causes of Low ALT

Low ALT levels are occasionally noted and may be clinically significant [2]:

• Vitamin B6 deficiency: As ALT is a cofactor-dependent enzyme, deficiency leads to reduced activity.

• Advanced liver disease: End-stage cirrhosis may result in the loss of enough functional hepatocytes to lower enzyme levels.

• Chronic kidney disease: Associated with lower ALT activity and uremia.

• Malnutrition: Protein deficiency and frailty often correlate with lower levels.

• Pregnancy: Physiological decreases occur due to hemodilution.

• Cancers and Aging: Naturally reduced hepatic synthesis or age-related declines can lead to lower values.

Limitations and Interferences

Laboratory results must be interpreted within the context of potential interferences [2]:

• Hemolysis: Significant interference can occur, as noted above.

• Bilirubin: Levels below 30 mg/dL do not show significant interference.

• Lipemia: Samples with lipemia level <3+ do not demonstrate significant interference.

• Other factors: Clinicians should refer to specific medical guidelines for potential interferences caused by specific pharmaceuticals or other preanalytical variables [2].

For Non-Medicos: Understanding Your ALT Test

If your doctor has ordered an ALT (SGPT) test, it is simply a way to check how well your liver is functioning [2]. Think of ALT as an enzyme that stays safely inside your liver cells [2]. When those cells become stressed, injured, or damaged, they leak this enzyme into your blood [2, 5]. By measuring the amount of ALT in your blood, doctors get a “snapshot” of your liver health [2].

What to know before your test:

• Preparation: Avoid intense exercise, heavy drinking, or fatty meals right before your blood draw, as these can make the results inaccurate [2].

• Why it’s done: It helps doctors screen for things like fatty liver, hepatitis, or the side effects of certain medications [5, 11].

• Don’t panic: An “elevated” result doesn’t always mean permanent damage [5]. Sometimes it is mild and linked to lifestyle factors like weight or diet [8, 14]. Your doctor will use this test alongside others (like your history, symptoms, or imaging) to build a full picture [5].

The Bottom Line: This is a routine diagnostic tool [2]. By identifying issues early through this simple blood test, you and your doctor can take proactive steps toward better health, such as adjusting your diet, managing medications, or treating underlying conditions [1, 11]. Always discuss your specific results with your healthcare provider for the most accurate medical advice.

References:

1. Al-Busafi, S. A., Alwassief, A., & Al-Azri, M. (2024). An update on the role of alanine aminotransferase in the detection of chronic liver diseases relevant to primary care. Oman Medical Journal, 40(1), e2025.46. https://doi.org/10.5001/omj.2025.46 Cited by: 2

2. Moriles, K. E., & Futterman, C. (2026). Alanine aminotransferase (ALT) test. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK559278/ Cited by: 62

3. Botros, M., & Sikaris, K. A. (2013). The De Ritis ratio: The test of time. Clinical Biochemistry Review, 34(3), 117–130. https://pmc.ncbi.nlm.nih.gov/articles/PMC3866949/ Cited by: 709

4. Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S., & Seeff, L. B. (2000). Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, monitoring, and prognosis of particular liver diseases. Clinical Chemistry, 46(12), 2050–2068.

5. Pratt, D. S., & Kaplan, M. M. (2000). Evaluation of abnormal liver-enzyme results in asymptomatic patients. New England Journal of Medicine, 342(17), 1266–1271.

6. Giannini, E. G., Testa, R., & Savarino, V. (2005). Liver enzyme alteration: A guide for clinicians. Canadian Medical Association Journal, 172(3), 367–379.

7. Angulo, P., & Keach, J. C. (2002). Noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. Seminars in Liver Disease, 22(4), 373–384.

8. Kim, H. C., Kang, J. H., Nam, C. M., Jee, S. H., & Kim, K. S. (2008). Elevated serum aminotransferase level as a predictor of intracellular adhesion molecule-1 and metabolic syndrome. Annals of Epidemiology, 18(3), 209–215.

9. Ruhl, C. E., & Everhart, J. E. (2009). The association of metabolic syndrome with appendicitis and gallbladder disease. American Journal of Gastroenterology, 104(11), 2736–2744.

10. Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24(2), 289–293.

11. American Association for the Study of Liver Diseases (AASLD). (2018). Diagnosis and management of nonalcoholic fatty liver disease: 2018 practice guidance. Hepatology, 67(1), 328–357.

12. World Health Organization. (2017). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection.

13. European Association for the Study of the Liver (EASL). (2016). EASL clinical practice guidelines on the management of non-alcoholic fatty liver disease. Journal of Hepatology, 64(6), 1388–1402.

14. Prospective Studies Collaboration. (2007). Metabolic syndrome and liver disease: A global perspective. The Lancet, 370(9590), 829–836.

15. Clark, J. M., Brancati, F. L., & Diehl, A. M. (2003). The prevalence and etiology of elevated aminotransferase levels in the United States. American Journal of Gastroenterology, 98(5), 960–967.

FAQ’s:

• What is SGPT?
  SGPT, or ALT, is an enzyme primarily found in the liver, indicating liver health.

• Why test ALT levels?
  It helps diagnose and monitor liver diseases like hepatitis and fatty liver.

• What is De Ritis ratio?
  It is the ratio of AST to ALT, used to assess liver disease causes.

• When is ALT released?
  ALT enters the bloodstream when liver cells are damaged or injured.

• Symptoms of liver damage?
  Common symptoms include jaundice, fatigue, nausea, abdominal pain, and dark-colored urine.

• How to prepare for test?
  Avoid alcohol, high-lipid diets, and strenuous exercise before your blood collection.

• Does hemolysis affect results?
  Yes, hemolysis releases ALT from red blood cells, potentially increasing serum levels.

• Causes of high ALT?
  Viral hepatitis, alcoholic liver disease, obesity, and certain medications can cause high levels.

• Can exercise raise ALT?
  Yes, strenuous physical activity before blood collection can artificially increase ALT levels.

• What means elevated ALT?
  Levels over 40 U/L typically indicate some degree of liver injury or stress.